文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

双侧肾上腺静脉采血成功的原发性醛固酮增多症患者通过单侧肾上腺切除术可获得更好的治疗效果。

Primary aldosteronism patients with bilateral adrenal vein sampling success achieve better outcomes through unilateral adrenalectomy.

作者信息

Sun Zhipeng, Hong Baoan, Wang Yuxuan, Zhang Xuezhou, Wang Wei, Miao Qi, Li Mingchuan, Bo Yuxuan, Zhang Ning

机构信息

Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

出版信息

Transl Androl Urol. 2025 Jun 30;14(6):1503-1519. doi: 10.21037/tau-2025-89. Epub 2025 Jun 19.


DOI:10.21037/tau-2025-89
PMID:40687666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12271940/
Abstract

BACKGROUND: Adrenal vein sampling (AVS) is the gold standard for diagnosing the dominant side in patients with primary aldosteronism (PA). encodes aldosterone synthase. The aim of this study was to investigate the prognosis of dominant-side adrenalectomy in patients with PA identified by AVS in the context of aldosterone synthase expression in the postoperative pathology of those patients. METHODS: This retrospective study included 73 PA patients who underwent AVS followed by unilateral adrenalectomy. Patients were categorized into AVS bilateral success group, AVS unilateral success group, and AVS bilateral failure group based on their AVS status. Immunohistochemistry (IHC) for CYP11B2 was combined with postoperative pathology in these patients, and the clinical and biochemical prognosis of these patients was assessed 6 months after adrenalectomy. RESULTS: Between September 2023 and September 2024, 73 patients underwent unilateral adrenalectomy guided by AVS at our institution, with CYP11B2 IHC successfully performed in 63 cases. Among these, 21 patients (33.33%) achieved bilateral AVS success, 20 (31.75%) demonstrated unilateral AVS success, and 22 (34.92%) exhibited bilateral AVS failure. Pathological analysis of the bilateral AVS success group revealed aldosterone-producing adenoma (APA) in 12 cases, aldosterone-producing micronodule (APM) in 1, multiple-aldosterone-producing micronodules/nodules (MAPM/MAPN) in 2, aldosterone-producing diffuse hyperplasia (APDH) in 1, APA with MAPM in 3, and APA with APDH in 2. In this group, complete and partial clinical success rates were 47.62% (10/21) and 52.38% (11/21), respectively, while biochemical success rates reached 95.24% (20/21) for complete and 4.76% (1/21) for partial success. The unilateral AVS success cohort included APA (n=8), aldosterone-producing nodule (APN) (n=2), MAPM/MAPN (n=3), APA with MAPM (n=4), APA with APDH (n=2), and 1 CYP11B2 IHC-negative lesion, with clinical success rates of 40.00% (8/20) complete and 60.00% (12/20) partial, alongside 90.00% (18/20) complete and 10.00% (2/20) partial biochemical success. The bilateral AVS failure group comprised APA (n=8), MAPM/MAPN (n=1), APA with MAPM (n=5), APA with APDH (n=2), and 6 CYP11B2 IHC-negative lesions, demonstrating 36.36% (8/22) complete, 50.00% (11/22) partial, and 13.64% (3/22) no clinical success, with biochemical outcomes of 72.73% (16/22) complete, 18.18% (4/22) partial, and 9.09% (2/22) no success. Notably, bilateral AVS success correlated with significantly superior biochemical outcomes compared to bilateral failure (P=0.045). CONCLUSIONS: Adrenalectomy guided by AVS yields better outcomes in patients with PA when AVS is successful on both sides compared to those with bilateral AVS failure. The source of excess aldosterone secretion on the dominant side identified by AVS is not necessarily an APA/APN. It may also include MAPM/MAPN, diffuse adrenal cortical hyperplasia, and various complex combined conditions. In patients with bilateral AVS failure, adrenal specimens more frequently exhibit negative immunohistochemical staining for CYP11B2.

摘要

背景:肾上腺静脉采血(AVS)是诊断原发性醛固酮增多症(PA)患者优势侧的金标准。编码醛固酮合酶。本研究的目的是在PA患者术后病理中醛固酮合酶表达的背景下,探讨经AVS确定优势侧的肾上腺切除术患者的预后。 方法:这项回顾性研究纳入了73例行AVS后接受单侧肾上腺切除术的PA患者。根据AVS情况,将患者分为AVS双侧成功组、AVS单侧成功组和AVS双侧失败组。对这些患者进行CYP11B2免疫组织化学(IHC)检查并结合术后病理,在肾上腺切除术后6个月评估这些患者的临床和生化预后。 结果:2023年9月至2024年9月,我院73例患者在AVS引导下接受了单侧肾上腺切除术,其中63例成功进行了CYP11B2 IHC检查。其中,21例(33.33%)实现双侧AVS成功,20例(31.75%)表现为单侧AVS成功,22例(34.92%)出现双侧AVS失败。双侧AVS成功组的病理分析显示,12例为醛固酮瘤(APA),1例为醛固酮生成微结节(APM),2例为多发性醛固酮生成微结节/结节(MAPM/MAPN),1例为醛固酮生成弥漫性增生(APDH),3例为APA合并MAPM,2例为APA合并APDH。该组完全和部分临床成功率分别为47.62%(10/21)和52.38%(11/21),而生化成功率完全成功为95.24%(20/21),部分成功为4.76%(1/21)。单侧AVS成功队列包括APA(n = 8)、醛固酮生成结节(APN)(n = 2)、MAPM/MAPN(n = 3)、APA合并MAPM(n = 4)、APA合并APDH(n = 2)以及1例CYP11B2 IHC阴性病变,临床成功率完全成功为40.00%(8/20),部分成功为60.00%(12/20),生化成功率完全成功为90.00%(18/20),部分成功为10.00%(2/20)。双侧AVS失败组包括APA(n = 8)、MAPM/MAPN(n = 1)、APA合并MAPM(n = 5)、APA合并APDH(n = 2)以及6例CYP11B2 IHC阴性病变,完全临床成功率为36.36%(8/22),部分临床成功率为50.00%(11/22),无临床成功率为13.64%(3/22),生化结果为完全成功72.73%(16/22),部分成功18.18%(4/22),无成功9.09%(2/22)。值得注意的是,与双侧失败相比,双侧AVS成功与显著更好的生化结果相关(P = 0.045)。 结论:与双侧AVS失败的患者相比,AVS引导下的肾上腺切除术在双侧AVS成功的PA患者中产生更好的结果。AVS确定的优势侧过量醛固酮分泌的来源不一定是APA/APN。它还可能包括MAPM/MAPN、弥漫性肾上腺皮质增生以及各种复杂的合并情况。在双侧AVS失败的患者中,肾上腺标本更频繁地表现出CYP11B2免疫组织化学染色阴性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/f969262adfb1/tau-14-06-1503-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/79969edd7f1d/tau-14-06-1503-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/1c53e90f37c3/tau-14-06-1503-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/ca201c5599f4/tau-14-06-1503-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/ee0f5789971d/tau-14-06-1503-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/3daecd5c4ea3/tau-14-06-1503-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/f969262adfb1/tau-14-06-1503-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/79969edd7f1d/tau-14-06-1503-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/1c53e90f37c3/tau-14-06-1503-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/ca201c5599f4/tau-14-06-1503-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/ee0f5789971d/tau-14-06-1503-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/3daecd5c4ea3/tau-14-06-1503-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43f2/12271940/f969262adfb1/tau-14-06-1503-f6.jpg

相似文献

[1]
Primary aldosteronism patients with bilateral adrenal vein sampling success achieve better outcomes through unilateral adrenalectomy.

Transl Androl Urol. 2025-6-30

[2]
Histopathological evaluation based on CYP11B2 staining predicts outcomes in unilateral primary aldosteronism.

Eur J Endocrinol. 2025-5-30

[3]
Comparison of Adrenal Vein Sampling Methods for Subtyping of Primary Aldosteronism: A Retrospective Observational Study.

Cardiovasc Intervent Radiol. 2025-7

[4]
Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism.

Ann Intern Med. 2009-9-1

[5]
Molecular Imaging Versus Adrenal Vein Sampling for the Detection of Surgically Curable Primary Aldosteronism : A Prospective Within-Patient Trial.

Ann Intern Med. 2025-3

[6]
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.

Lancet Diabetes Endocrinol. 2017-5-30

[7]
Case Report: Anomalous drainage vein sampling for diagnosing aldosterone-producing lesions undetectable by segmental adrenal venous sampling in a two-case series.

Front Radiol. 2025-6-10

[8]
Antecubital versus femoral approach for adrenal venous sampling in the patients with primary aldosteronism: a randomized controlled trial.

Int J Surg. 2025-7-1

[9]
Comparison of three approaches for adrenal venous sampling in patients with primary aldosteronism.

J Endocrinol Invest. 2025-3-15

[10]
Performance of Pentixafor PET/CT in identifying unilateral primary aldosteronism: A meta-analysis.

Eur J Radiol. 2025-9

本文引用的文献

[1]
Adrenalectomy for primary aldosteronism and its related surgical characteristics.

Front Endocrinol (Lausanne). 2024

[2]
Genetic Deletion of β-Arrestin 2 From the Subfornical Organ and Other Periventricular Nuclei in the Brain Alters Fluid Homeostasis and Blood Pressure.

Hypertension. 2024-6

[3]
Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document.

Endocrine. 2024-8

[4]
Diagnostic consistency between computed tomography and adrenal vein sampling of primary aldosteronism: leading to successful curative outcome after adrenalectomy; a retrospective study.

Int J Surg. 2024-2-1

[5]
Success Rate of Adrenal Venous Sampling and its Determining Factors: Experience of a Single Center in Malaysia.

Ann Vasc Surg. 2024-1

[6]
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.

Endocr Rev. 2024-1-4

[7]
Mineralocorticoid receptor signalling in primary aldosteronism.

J Endocrinol. 2023-9-1

[8]
Adrenal Venous Sampling Via an Antecubital Approach in Primary Aldosteronism: A Multicenter Study.

J Clin Endocrinol Metab. 2023-12-21

[9]
[History, current situation and disputes over adrenal vein sampling in the diagnosis and treatment of primary aldosteronism].

Zhonghua Nei Ke Za Zhi. 2022-10-1

[10]
Primary aldosteronism - a multidimensional syndrome.

Nat Rev Endocrinol. 2022-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索